Yttrium-90 Microsphere Radioembolization

PROCEDURE6 trials

Sponsors

Thomas Jefferson University, Nicholas Fidelman, MD, M.D. Anderson Cancer Center, OHSU Knight Cancer Institute, Emory University

Conditions

Anatomic Stage IV Breast Cancer AJCC v8Hepatocellular CarcinomaLocally Advanced Intrahepatic CholangiocarcinomaMetastatic Breast CarcinomaMetastatic Carcinoma in the LiverMetastatic Malignant Neoplasm in the LiverNeuroendocrine NeoplasmOligometastatic Intrahepatic Cholangiocarcinoma

Phase 1

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

RecruitingNCT06058663

Mayo ClinicLocally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8 +2

Start: 2024-06-06End: 2028-11-30Target: 16Updated: 2025-10-17

Phase 2

Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

CompletedNCT03199274

Thomas Jefferson UniversityHepatocellular Carcinoma

Start: 2017-07-01End: 2025-01-23Updated: 2026-01-02

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Active, not recruitingNCT03457948

Nicholas Fidelman, MDMetastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm

Start: 2018-08-27End: 2026-05-31Updated: 2025-09-03

Y-90 Versus SBRT for Inoperable HCC

WithdrawnNCT05157451

OHSU Knight Cancer InstituteHepatocellular Carcinoma, Stage IA Hepatocellular Carcinoma AJCC v8, Stage IB Hepatocellular Carcinoma AJCC v8 +6

Start: 2023-12-01End: 2026-01-05Updated: 2023-03-23

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

WithdrawnNCT05315687

Emory UniversityAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver +1

Start: 2022-08-17End: 2025-07-31Updated: 2024-01-19

Unknown Phase

Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)

Active, not recruitingNCT03896646

M.D. Anderson Cancer CenterStage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8 +4

Start: 2019-10-10End: 2026-09-30Updated: 2025-11-21

Related Papers

Abstract 6455: Cytotoxic T-cell signatures underlie therapeutic response to 177Lu-DOTATATE plus pembrolizumab in well-differentiated gastroenteric neuroendocrine tumors

Cancer Research2026-04-03

Microbubble-based Radiosensitization of Hepatocellular Carcinoma: Evaluation of Safety and Efficacy in a Phase II Randomized Trial.

2025-09-012 citations

Abstract CT189: Yttrium-90 radioembolization in combination with tremelimumab and durvalumab for treating patients with locally advanced, unresectable or oligo-metastatic intrahepatic cholangiocarcinoma who are not candidates for curative therapy

Cancer Research2025-04-25

Radiation enhancement using focussed ultrasound-stimulated microbubbles for breast cancer: A Phase 1 clinical trial

PLoS Medicine2024-05-1724 citations

Study Protocol: Efficacy and Safety of Radioembolization (REM) as an Early Modality (EM) Therapy for Metastatic Breast Cancer (BR) to the Liver with Y90 (REMEMBR Y90).

2022-08-252 citations

ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs).

2022-07-201 citations